ReviewFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026
Targeting Arterial Dysfunction in Cardiovascular Disease Using Stem Cell-Based Therapies.
Review in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Arterial regeneration represents a critical frontier in cardiovascular medicine, as progressive endothelial dysfunction, maladaptive vascular smooth muscle cell (SMC) plasticity, and chronic inflammation drive atherosclerosis, restenosis, and vascular aging. Although current therapies such as pharmacological risk-modifying therapies and interventional revascularization procedures mitigate the risk and delay the progression, they are still unable to restore vascular integrity. Stem cell-based strategies were initially conceived to replace the lost vascular cells directly; however, accumulating evidence indicates their therapeutic benefits arise from paracrine mechanisms including regulation of endothelial repair, modulation of SMC phenotypic switching, and attenuation of inflammatory signaling. This paradigm shift has expanded the regenerative landscape to encompass endothelial progenitor cells, mesenchymal stromal cells, induced pluripotent stem cell-derived vascular lineages, and engineered extracellular vesicle platforms. Parallel advances in biomaterials, mechanically tuned scaffolds, and hybrid cell-matrix constructs provide more physiologic microenvironments for vascular repair and enhance the retention, potency, and safety of regenerative therapies. Concurrently, gene editing, metabolic reprogramming, and hypoxic preconditioning further refine the functional capacity of stem cell-derived products, enabling targeted correction of endothelial instability and improving regulation of vascular remodeling. Integration of multi-omic profiling and high-resolution vascular phenotyping now positions the field to align regenerative strategies with patient-specific determinants of disease. This review integrates current knowledge on stem cell-mediated endothelial regeneration, SMC phenotype regulation, and bioengineered vascular interventions, and examines emerging precision-medicine frameworks poised to guide next-generation therapies that link mechanistic principles with translational progress to enable durable restoration of arterial structure and function, and long-term vascular health, thereby providing a theoretical basis for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.